IQVIA (NYSE:IQV) Issues Quarterly Earnings Results, Beats Estimates By $0.12 EPS

IQVIA (NYSE:IQV) issued its quarterly earnings data on Tuesday. The medical research company reported $3.15 earnings per share for the quarter, topping the consensus estimate of $3.03 by $0.12, FiscalAI reports. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the previous year, the firm posted $2.81 earnings per share. The firm’s revenue for the quarter was up 8.7% on a year-over-year basis. IQVIA updated its FY 2026 guidance to 12.800-13.000 EPS.

Here are the key takeaways from IQVIA’s conference call:

• Second-quarter results exceeded guidance: Revenue rose 8.7% reported and 8.5% at constant currency, while adjusted EBITDA increased 9.2% and adjusted EPS grew 12.1% to $3.15, driven by operational execution.
• Full-year 2026 guidance was raised for revenue to $17.275–$17.475 billion, adjusted EBITDA to $4.0–$4.05 billion, and adjusted EPS to $12.80–$13.00; the company maintained its expectation for approximately flat adjusted EBITDA margins.
• R&D Solutions bookings strengthened substantially, with net new bookings up 19.3% year over year to $3.15 billion, a 1.22 book-to-bill ratio, and trailing-12-month bookings up 12.9%; management cited broad-based demand, improving win rates, and strong emerging-biopharma funding.
• Commercial Solutions organic growth accelerated to 5%, supported by new drug launches, double-digit growth in engagement services and patient solutions, and rising adoption of AI offerings; management said pipelines, decision timelines, and win rates are all improving.
• Productivity initiatives generated about 90 basis points of underlying margin improvement in the quarter, but pass-through costs created an approximately 80-basis-point headwind. IQVIA is also reviewing its backlog for inactive trials and expects any potential adjustment—currently estimated near 5%—to have no effect on historical results, guidance, or next-12-month revenue-from-backlog metrics.

IQVIA Stock Performance

Shares of IQVIA stock opened at $248.61 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock’s fifty day moving average is $190.47 and its two-hundred day moving average is $186.86. IQVIA has a 52 week low of $154.50 and a 52 week high of $247.72. The company has a market capitalization of $41.49 billion, a PE ratio of 30.48, a price-to-earnings-growth ratio of 1.91 and a beta of 1.20.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. HSBC reiterated a “buy” rating and issued a $240.00 target price on shares of IQVIA in a report on Monday, July 6th. Barclays restated an “overweight” rating on shares of IQVIA in a research report on Tuesday. Mizuho boosted their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Finally, Evercore restated an “outperform” rating and issued a $185.00 target price on shares of IQVIA in a report on Wednesday, April 8th. Thirteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $227.94.

IQVIA declared that its board has initiated a share buyback plan on Thursday, May 7th that allows the company to buyback $2.00 billion in shares. This buyback authorization allows the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

IQVIA News Roundup

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Second-quarter earnings and revenue beat expectations. IQVIA reported adjusted EPS of $3.15, above the $3.02–$3.03 consensus range, while revenue reached $4.37 billion versus approximately $4.30 billion expected. Revenue grew 8.7% year over year, and EPS increased from $2.81 in the prior-year quarter. IQVIA Reports Second-Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 earnings guidance. IQVIA now expects full-year EPS of $12.80 to $13.00, above the prior consensus estimate of $12.57. Revenue guidance was set at $17.3 billion to $17.5 billion, broadly in line with expectations. IQVIA stock gains on Q2 beat and guidance hike
• Positive Sentiment: Bookings and backlog point to sustained demand. Record research-and-development bookings, broad-based growth and a ballooning backlog supported the improved outlook, suggesting stronger future revenue visibility for IQVIA’s clinical-research business. IQV Q2 earnings beat estimates on R&D bookings
• Positive Sentiment: Analyst sentiment improved. Robert W. Baird raised its price target from $252 to $287 and maintained an “Outperform” rating, indicating potential additional upside based on the stronger earnings and outlook.
• Neutral Sentiment: Valuation is receiving greater investor attention. With IQVIA trading near its 12-month high and at a reported price-to-earnings ratio of about 30, the earnings beat and guidance increase must continue to justify the stock’s higher valuation. IQVIA Holdings earnings beat keeps fair value in focus

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IQV. Gilpin Wealth Management LLC purchased a new position in IQVIA in the 4th quarter worth about $27,000. CrossGen Wealth LLC purchased a new stake in IQVIA in the 4th quarter valued at about $28,000. Measured Wealth Private Client Group LLC bought a new position in IQVIA in the 3rd quarter worth about $30,000. Johnson Financial Group Inc. purchased a new position in shares of IQVIA during the third quarter worth approximately $52,000. Finally, DV Equities LLC bought a new stake in shares of IQVIA during the fourth quarter valued at approximately $53,000. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.